ICD-10 Coding for Neuroendocrine Tumors(E34.0U)
Explore detailed ICD-10 coding guidelines for neuroendocrine tumors, including malignant and benign classifications, documentation requirements, and common coding pitfalls.
Complete code families applicable to Neuroendocrine Tumors
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C7A.01 | Malignant carcinoid tumor of the small intestine | Use when a malignant carcinoid tumor is confirmed in the small intestine. |
|
| C7A.1 | Poorly differentiated neuroendocrine tumors | Use when a neuroendocrine tumor is poorly differentiated. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutNeuroendocrine Tumors
Documentation & Coding Risks
Avoid these common issues when documenting Neuroendocrine Tumors.
Omitting tumor grade in documentation
Impact
Clinical: May lead to inappropriate treatment planning., Regulatory: Non-compliance with documentation standards., Financial: Potential for incorrect coding and billing.
Mitigation
Ensure pathology reports include grade, Train staff on documentation standards
Using the Neoplasm Table instead of the alphabetic index
Impact
Reimbursement: Incorrect coding can lead to inappropriate DRG assignment., Compliance: May result in non-compliance with coding guidelines., Data Quality: Affects the accuracy of clinical data.
Mitigation
Always refer to the alphabetic index for neuroendocrine tumors.
Documentation of tumor characteristics
Impact
Incomplete documentation of tumor differentiation and grade.
Mitigation
Implement regular audits and training sessions.